Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular EDEMA

Retina

Volumn 29, Issue 1, 2009, Pages 33-37

  Barone, Antonio ^a,b   Russo, Vincenzo ^a   Prascina, Francesco ^a   Noci, Nicola Delle ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Ospedali Riuniti di Foggia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MACULAR THICKNESS; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA CYSTOID EDEMA; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; CASE REPORT; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; INJECTION; LENS IMPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PSEUDOPHAKIA; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT EXTRACTION; FEASIBILITY STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; LENS IMPLANTATION, INTRAOCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PSEUDOPHAKIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 61549103753     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31818a1fbc     Document Type: Article

References (23)

1. Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 1995;21: 59 -63.
2. Jampol LM. Pharmacologic therapy of aphakic and pseu-dophakic cystoid macular edema: 1985 update. Ophthalmology 1985;103:1134-1135.
3. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.
4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
5. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47:S203-S218.
6. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are cor- related with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-315.
7. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinop-athy in the nonhuman primate. Am J Ophthalmol 2002;133: 373-385.
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
9. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
10. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevaci-zumab (Avastin) therapy for neovascular age-related macular degeneration; twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bev-acizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
12. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevaci-zumab (Avastin) treatment of macular edema in central retinal vein occlusion; a short-term study. Retina 2006;26:279-284.
13. Mason JO III, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
14. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
15. Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
16. Fung WE, Custis PH. Aphakic and pseudophakic cystoid mac-ular edema. In: Ryan SJ, ed, Retina. 2nd ed. St Louis, MO: C.V. Mosby; 1994:1797-1810.
17. Reis A, Birnbaum F, Hansen LL, et al. Successful treatment of cystoid macular edema with valdecoxib. J Cataract Refract Surg 2007;33:682-685.
18. Jonas JB, Kreissig I, Denenring RF. Intravitreal triamcinolone for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384 -386.
19. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47(suppl 1):S203-S218.
20. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378 -2384.
21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
22. Spitzer MS, Ziemssen F, Yoeruek E, et al. Efficacy of intra-vitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008;34: 70-75.
23. Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intra-vitreal bevacizumab for the management of pseudophakic cys-toid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33: 2098-2105.